Developing new antibodies to help deliver drugs to the brain
New Human Antibodies for CNS Drug Delivery
['FUNDING_R01'] · UNIVERSITY OF WISCONSIN-MADISON · NIH-11066451
This study is exploring new ways to help medicines get into the brain more effectively, which could lead to better treatments for people with Alzheimer's and stroke.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF WISCONSIN-MADISON (nih funded) |
| Locations | 1 site (MADISON, UNITED STATES) |
| Trial ID | NIH-11066451 on ClinicalTrials.gov |
What this research studies
This research focuses on overcoming the challenges posed by the blood-brain barrier (BBB) that limits the effectiveness of treatments for neurological diseases like Alzheimer's and stroke. By identifying and validating new antibodies that can effectively transport therapeutic agents across the BBB, the research aims to enhance drug delivery to the brain. The approach involves linking these antibodies to drug payloads, allowing them to utilize natural transport mechanisms to reach their target. Patients may benefit from improved treatment options for conditions that currently have limited therapeutic access.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals suffering from neurological conditions such as Alzheimer's disease, stroke, or brain cancer.
Not a fit: Patients with neurological conditions that do not involve the blood-brain barrier or those who do not respond to antibody-based therapies may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for neurological diseases by enabling better drug delivery to the brain.
How similar studies have performed: Previous research has shown promise in using antibody-mediated transport for drug delivery across the BBB, indicating potential for success in this novel approach.
Where this research is happening
MADISON, UNITED STATES
- UNIVERSITY OF WISCONSIN-MADISON — MADISON, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: SHUSTA, ERIC V — UNIVERSITY OF WISCONSIN-MADISON
- Study coordinator: SHUSTA, ERIC V
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Acquired Immune Deficiency Syndrome, Acquired Immunodeficiency Syndrome, Alzheimer disease dementia, Alzheimer syndrome, Alzheimer's Disease